
Despite viral videos, methylene blue won't improve your mood or cognition, experts say
Methylene blue received significant social media attention after a video began circulating in February showing U.S. Health and Human Services Secretary Robert F. Kennedy Jr. using a dropper to add a blue liquid to a glass of water.
"To anyone who knows anything about chemistry, you look at that video and it's very clear that he's squirting methylene blue into the glass," said Joe Schwarcz, director of McGill University's Office for Science and Society, speaking with Dr. Brian Goldman, host of The Dose podcast.
Health and wellness influencers, including podcasters like Joe Rogan, quickly began suggesting that, taken orally, methylene blue could be used to improve cognition, minimize the signs of aging and even — in the case of controversial filmmaker Mel Gibson — fight cancer.
Despite the attention it has received, experts say that people shouldn't take methylene blue unless under the supervision of a medical professional.
What is methylene blue?
First synthesized in the late 1800s by German chemist Heinrich Car o, methylene blue began its life as a textiles dye. But it was soon discovered it could stain microbes under a microscope, making them easier to see and study.
After methylene blue was found to not only stain but actually kill one of the parasites that causes malaria, the dye took on a new life as a treatment for the mosquito-borne disease, Schwarcz says.
"It competed with quinine, but it was much cheaper to produce," said Schwarcz, who has a PhD in chemistry and also teaches at McGill.
"By playing around with the molecular structure, sort of molecular roulette, [chemists] were able to change the structure of the molecule eventually into chloroquine, which is still widely used today to treat malaria."
Because of this, methylene blue remains on the World Health Organization's Model List of Essential Medicines.
How else is methylene blue used today?
Modern physicians now mostly know it as a treatment for methemoglobinemia, a rare condition that occurs when the blood is unable to adequately carry oxygen throughout the body.
"Methylene blue is effective at … helping them restore the balance to a normal amount of oxygenated hemoglobin or deoxygenated hemoglobin," said Dr. Emily Austin, a Toronto-based emergency physician and medical director of the Ontario Poison Centre.
Drugs like dapsone, used to treat leprosy and certain kinds of dermatitis, as well as substances like amyl nitrites — found in party drugs like poppers, as well as in soil runoff contaminated by fertilizers — can cause methemoglobinemia.
Topical anesthetics can also sometimes cause chemical changes in the body that lead to methemoglobinemia, says Austin.
WATCH | Not sure if that online health advice is legit? Watch this:
Not sure if that online health advice is legit? Watch this
3 months ago
Duration 1:56
Symptoms of methemoglobinemia include blue lips or blue fingertips, shortness of breath, confusion and fainting. Patients may even have a distinct chocolate colour to their blood.
Austin says methemoglobinemia is relatively rare, and she has seen it only once since she began working as an emergency physician in 2016, though she adds that the condition is seen more frequently at the Ontario Poison Centre.
"In general, it's still a fairly rare occurrence," said Austin.
"This is not something that somebody would necessarily see in their career as a practising emergency physician, although it's common enough that I think it's important we have an approach to it."
Is there anything to the claims methylene blue can prevent Alzheimer's?
Some social media claims have suggested methylene blue can be effective in preventing and treating Alzheimer's disease.
Schwarcz, however, says the link between methylene blue and Alzheimer's is more complicated than Tiktok might suggest.
One of the telltale neurological signs of Alzheimer's disease is the tangling of tau proteins in the brain.
"It turns out that methylene blue was not only able to visualize and stain those tangled proteins that characterize Alzheimer's disease, but, amazingly, under the microscope … it actually untangled those proteins," said Schwarcz.
However, research has shown that ingesting methylene blue orally does little to improve symptoms of Alzheimer's.
What has shown some promise in very early research on animals, Schwarcz said, is a derivative of methylene blue created by altering its molecular structure.
"There have been a couple of pilot studies on humans where it seems that the deterioration in terms of Alzheimer's was slowed down somewhat," he said.
"But we need a lot more work there."
A 2023 comprehensive review of randomized control trials examining the effects of methylene blue and its derivatives on Alzheimer's treatment highlighted the compound's "potential to improve cognitive function, reduce oxidative stress, and protect against neurodegeneration."
Nonetheless, the same paper pointed out several concerns, among them safety issues and adverse effects — including mild to moderate gastrointestinal and urinary effects — while simultaneously highlighting the need for studies with larger sample sizes, longer treatment durations and an examination of proper dosages and administration routes.
For his part, Schwarcz says not only does the commercially available methylene blue bear little resemblance to the derivative included in that research, there's little benefit to taking it until better, longer-term research shows that it actually can improve brain health.
"I can't say that there's no long-term risk, because no one has ever studied this over the long-term," said Schwarcz.
Methylene blue and SSRIs
Austin, however, says people taking selective serotonin reuptake inhibitors (SSRI), a class of medication typically used to treat depression, should avoid consuming methylene blue.
That's because taking it along with SSRIs inhibits the breakdown of serotonin, and can lead to a condition known as serotonin toxicity, says Austin.
Serotonin is a neurotransmitter that, among other functions, plays a role in regulating mood, cognition and memory.
Too much serotonin circulating in the body — sometimes called serotonin syndrome — can lead to higher or lower heart rate, high blood pressure, increased body temperature, as well as changes in the behaviour of muscles and reflexes, Austin says.
She says concerns around serotonin toxicity are one of the reasons why she might avoid treating her patients with methylene blue.
WATCH | Teen fact checkers take on fake TikTok posts:
Teen fact checkers take on fake TikTok posts
1 year ago
Duration 2:00
An elite teen squad of fact checkers with the help of media literacy organizations are learning to suss out scams and fake information on TikTok, making videos to teach other teens about misinformation online.
Poor scientific literacy behind proliferation of health misinformation
As someone who regularly works to combat health and other scientific misinformation, Schwarcz says a lack of scientific literacy is one of the reasons why social media users easily spread dubious information about methylene blue and other topics.
"They don't understand the underlying science, and they will make mountains out of molehills," said Schwarcz.
"Unfortunately, this is just the way things are working these days. Social media has taken over information spread."
At the same time, Schwarcz blames public figures like Robert F. Kennedy Jr. for aiding in the spread of misinformation.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Globe and Mail
an hour ago
- Globe and Mail
Why Viking Therapeutics Stock Zoomed 5% Higher Today
Key Points Good news from a peer and a positive analyst update were the elements driving Viking Therapeutics (NASDAQ: VKTX) stock higher on the first trading day of the week. The clinical-stage biotech, closely watched by some because of its investigational weight-loss drug VK2735, saw its share price improve by more than 5% as a result. By contrast, the S&P 500 index basically traded flat across the trading session. What's good for the goose... The news driving Viking and other obesity drug developers came from a leading company in that space, Wegovy maker Novo Nordisk. Late Friday, the Denmark-based pharmaceutical announced that Wegovy earned approval from the U.S. Food and Drug Administration (FDA) to treat a new indication, noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), a liver disorder. Companies like Viking and Novo Nordisk have been on the radar of many of an investor because of the obvious side benefits to obesity drugs. The latter company earning a fresh approval to treat a medical issue besides obesity provides a significant morale boost to shareholders of weight loss drug developers. Bullish stance reiterated Also improving sentiment on Viking stock was that new analyst note. Monday morning before market open, Piper Sandler 's Biren Amin reiterated his overweight (buy, in other words) recommendation and $71-per-share price target on the biotech. Amin's focus, according to reports, wasn't Novo Nordisk's recent news; rather, he was cheered by the prospects for VK2735. Viking is putting an oral version of the medication through clinical trials, and the readout of a phase 3 study is expected within this calendar quarter. In his estimation, if oral VK2735 continues to do well in testing and is brought to market, it could garner sales of $2.1 billion. Should you invest $1,000 in Viking Therapeutics right now? Before you buy stock in Viking Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 18, 2025


CTV News
6 hours ago
- CTV News
Federal funding boosts French-language nursing studies
Collège Boréal to receive $4.8 million from the Official Languages Health Program to expand its auxiliary nursing program, enhancing bilingual healthcare access in northern Ontario. The announcement was made Monday by Sudbury MP Viviane Lapointe.


Globe and Mail
7 hours ago
- Globe and Mail
Buy, Hold, or Fade the Recent Rally in UnitedHealth Group (UNH) Stock?
UnitedHealth Group UNH stock is still down 40% year to date but has surged more than +20% this month following reports that Warren Buffett's Berkshire Hathaway BRK.B and other billionaire hedge fund managers have taken a stake in the company, including David Tepper's Appaloosa Management. In a classic value investing move, Buffett undoubtedly sees long-term value in UnitedHealth Group as a high-quality business at a steep discount, investing in other industry leaders during a crisis like Goldman Sachs GS during the 2008 financial meltdown and more recently Occidental Petroleum OXY during the Covid-19 pandemic plunge in energy prices. To that point, UnitedHealth has faced a DOJ investigation stemming from its health services and technology subsidiary Optum, and had previously suspended its full-year financial guidance due to unexpectedly high medical costs. Considering such, investors may be weighing the pros and cons of investing in UNH, with some wondering if it's time to fade the recent rally. UnitedHealth's Attractive Valuation & Balance Sheet As the parent company of United Healthcare, the nation's largest insurer, UnitedHealth Group stock had recently fallen toward its decade low in terms of price to forward earnings and is still on par with its 10-year foward P/E median of 18X. Furthermore, UNH trades at less than 1X sales and has the scale, diversification, and cash flow that are likely attracting Buffett and other large investors to believe in its long-term recovery. Notably, UnitedHealth Group has more than $32 billion in cash and equivalents on hand and over $308 billion in total assets compared to $208.1 billion in total liabilities. UNH EPS Revisions Despite reinstating its guidance, UnitedHealth Group now expects full-year fiscal 2025 EPS to be considerably lower at a least $16 per share, with the Zacks Consensus currently at $16.58 and falling 25% over the last 60 days from expectations of $22.28. While the drop in FY25 EPS estimates was expected, what may be more concerning to investors is that FY26 EPS estimates have dropped nearly 30% in the last two months from projections of $25.58 to $18.08. Conclusion & Final Thoughts The institutional pile into UnitedHealth Group stock may have set a psychological floor for investors, but the trend of declining EPS revisions does take away from the company's enticing valuation and suggests there could still be much better buying opportunities ahead. Correlating with such, it may be time to fade the recent rally, with UNH landing a Zacks Rank #5 (Strong Sell) at the moment. For investors who may be interested in limiting the short-term risk associated with the recent volatility in UnitedHealth Group stock, Zacks analyst Sanghamitra Saha has alluded to the notion that the iShares U.S. Healthcare Providers ETF IHF could be a better way to get exposure to UNH. Free Report: Profiting from the 2nd Wave of AI Explosion The next phase of the AI explosion is poised to create significant wealth for investors, especially those who get in early. It will add literally trillion of dollars to the economy and revolutionize nearly every part of our lives. Investors who bought shares like Nvidia at the right time have had a shot at huge gains. But the rocket ride in the "first wave" of AI stocks may soon come to an end. The sharp upward trajectory of these stocks will begin to level off, leaving exponential growth to a new wave of cutting-edge companies. Zacks' AI Boom 2.0: The Second Wave report reveals 4 under-the-radar companies that may soon be shining stars of AI's next leap forward. Access AI Boom 2.0 now, absolutely free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report The Goldman Sachs Group, Inc. (GS): Free Stock Analysis Report Occidental Petroleum Corporation (OXY): Free Stock Analysis Report Berkshire Hathaway Inc. (BRK.B): Free Stock Analysis Report iShares U.S. Healthcare Providers ETF (IHF): ETF Research Reports